Search

everythinglearnresearchcommunity

for

Search:↓

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

A new AIRE gene mutation causes rare autoimmune symptoms in a Lebanese boy.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.

The study developed a mouse model for Alopecia Areata that responds to treatment, useful for future research.

Mathematical modeling helps understand and predict the MAPK cell signaling pathway.

Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.

Pannexin 3 is important for bone formation and the development of bone cells.

Auranofin shows promise as a cancer treatment, especially when combined with other therapies.

Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.

A Taiwanese patient had hair loss and skin bumps without the usual gene mutation, suggesting other genetic factors might be involved.

Prostaglandins and the enzyme AKR1C3 could play a role in skin cancer and hair loss, and further research is needed to understand these mechanisms.

The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.

Delta-opioid receptors affect skin cell circadian rhythms, possibly impacting wound healing and cancer.

FGFR2 signaling controls Merkel cell formation in different skin regions.

17β-estradiol boosts APE1/Ref-1 secretion in cells and mice via a calcium-dependent pathway.

Protein tyrosine kinases are key in male pattern baldness, affecting skin structure, hair growth, and immune responses.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

Significant progress was made in understanding PXE, but effective treatments are still needed.

New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

RANKL causes lymph nodes to grow by making certain cells multiply.

Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.

Runx1 is crucial for proper hair structure and development.

Krox20 is important for cell differentiation in the brain and hair follicles.